News Quantified

TNDM – tandem diabetes care, inc. (US:NASDAQ)

Tandem Diabetes Care (TNDM) had its "buy" rating reaffirmed by TD Cowen.

Tandem Diabetes Care (TNDM) had its price target lowered by The Goldman Sachs Group, Inc. from $28.00 to $25.00. They now have a "neutral" rating on the stock.

Assessing Tandem Diabetes Care (TNDM) Valuation After Recent Share Price Weakness [Yahoo! Finance]

Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026

Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}